Delaney Dennis R Invests $55,000 in Autolus Therapeutics PLC Sponsored ADR $AUTL

Delaney Dennis R purchased a new position in shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 24,000 shares of the company’s stock, valued at approximately $55,000.

Several other large investors also recently made changes to their positions in the stock. Wellington Management Group LLP boosted its stake in shares of Autolus Therapeutics by 6.9% during the 1st quarter. Wellington Management Group LLP now owns 27,091,700 shares of the company’s stock worth $41,992,000 after acquiring an additional 1,746,020 shares in the last quarter. Armistice Capital LLC boosted its stake in shares of Autolus Therapeutics by 19.6% during the 1st quarter. Armistice Capital LLC now owns 11,000,000 shares of the company’s stock worth $17,050,000 after acquiring an additional 1,800,000 shares in the last quarter. Atle Fund Management AB boosted its stake in shares of Autolus Therapeutics by 130.5% during the 2nd quarter. Atle Fund Management AB now owns 1,105,461 shares of the company’s stock worth $2,520,000 after acquiring an additional 625,817 shares in the last quarter. Cetera Investment Advisers boosted its stake in shares of Autolus Therapeutics by 47.3% during the 1st quarter. Cetera Investment Advisers now owns 524,872 shares of the company’s stock worth $814,000 after acquiring an additional 168,650 shares in the last quarter. Finally, Knott David M Jr bought a new stake in shares of Autolus Therapeutics during the 1st quarter worth about $651,000. Institutional investors own 72.83% of the company’s stock.

Autolus Therapeutics Trading Down 5.7%

Shares of AUTL stock opened at $1.66 on Monday. The stock has a 50 day moving average of $1.66 and a two-hundred day moving average of $1.78. Autolus Therapeutics PLC Sponsored ADR has a 12 month low of $1.11 and a 12 month high of $5.00. The company has a market capitalization of $441.79 million, a P/E ratio of -1.98 and a beta of 1.84.

Autolus Therapeutics (NASDAQ:AUTL) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.06. The firm had revenue of $13.50 million during the quarter, compared to the consensus estimate of $12.92 million. Sell-side analysts predict that Autolus Therapeutics PLC Sponsored ADR will post -0.94 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Autolus Therapeutics in a research note on Wednesday, October 8th. William Blair restated an “outperform” rating on shares of Autolus Therapeutics in a research note on Wednesday, September 24th. Wells Fargo & Company decreased their target price on Autolus Therapeutics from $6.00 to $5.00 and set an “overweight” rating for the company in a research note on Wednesday, August 13th. Needham & Company LLC restated a “buy” rating and set a $10.00 target price on shares of Autolus Therapeutics in a research note on Monday, July 21st. Finally, Wall Street Zen upgraded Autolus Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 16th. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $9.12.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.